Numerous lawsuits have been filed against Sanofi-Aventis alleging that its chemotherapy drug Taxotere may cause permanent hair loss (alopecia) or baldness in cancer patients.
Free Confidential Lawsuit Evaluation: If you or a loved one was injured by Taxotere side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
Update: Attorneys Ordered to Identify All Claimants for Possible Taxotere Settlement
September 18, 2017 – The Louisiana court in charge of overseeing the federal Taxotere litigation has ordered plaintiffs’ attorneys to identify all claimants in anticipation of a potential settlement in the hair loss lawsuits. The court further ordered all parties to immediately report on any new individuals with potential Taxotere lawsuits, even if the complaints have not yet been filed. Identifying and reporting all potential claims is required for participating in any settlements resulting from the litigation.
What is Taxotere?
Taxotere (generic: docetaxel) is a semi-synthetic chemotherapy drug that interferes with the growth and spread of cancer cells in the body. It is used to treat breast cancer, lung cancer, prostate cancer, stomach cancer, and head/neck cancer. Taxotere was approved by the U.S. Food & Drug Administration (FDA) in May 1996 for the treatment of metastatic breast cancer after prior chemotherapy treatments have failed.
What’s the Problem?
Hair loss, or alopecia, is a common side effect of chemotherapy. Scalp, pubic and axillary hair may be lost, as well as eyebrows and eyelashes. In most cases, alopecia is temporary and reversible, with complete hair regrowth within 3 to 6 months following the completion of chemotherapy. However, in recent years, many cases of permanent alopecia with no hair growth after 6 months have been reported in cancer patients treated with Taxotere.
Taxotere Alopecia Studies
- In 2006, a study conducted by Dr. Scot Sedlacek at the Rocky Mountain Cancer Centers in Colorado found that over 6% of breast cancer patients failed to grow back half their hair after undergoing chemo with Taxotere.
- A 2010 study published in the Journal of the American Academy of Dermatology suggested that Taxotere was the cause of an increasing number of permanent, chemotherapy-induced alopecia among cancer patients.
- The National Cancer Research Institute (NCRI) reported in 2013 that 10-15% of all patients treated with Taxotere experienced permanent, irreversible hair loss.
Sanofi Warned About Permanent Hair Loss in Europe, Canada
Sanofi-Aventis warned health officials in Europe (2005) and Canada (2012) about the potential for permanent hair loss with Taxotere, but failed to extend this warning to American consumers until December 2015. Prior to this, Taxotere labels in the U.S. stated that hair “generally grows back” after chemotherapy with Taxotere is complete.
Has a Class Action Been Filed?
Sanofi-Aventis is being investigated for failing to warn patients about the risk of permanent alopecia and baldness with Taxotere. To date, no class action lawsuit has been filed in the Taxotere litigation. However, our lawyers are accepting potential individual claims on behalf of injured parties.
While hair loss may seem like a small price to pay for a potentially life-saving drug, alopecia can make cancer survivors feel as though they are still living with the disease. Permanent hair loss from Taxotere is disfiguring for women, and causes extensive mental anguish, economic and psychological damages. This is unfair and unjust, and our attorneys are here to help victims of Taxotere through this difficult time.
Taxotere lawsuits allege that although hair loss is a known side effect of chemotherapy treatment, permanent alopecia is not. Plaintiffs claim that Sanofi, through its publications and marketing material, mislead the public and medical communities to believe that, as with other chemo drugs that cause hair loss, Taxotere users’ hair would grow back.
Taxotere MDL Surpasses 1,100 Alopecia Lawsuits
June 6, 2017 – The federal multidistrict litigation (MDL No. 2740) for lawsuits alleging permanent hair loss or “alopecia” from Taxotere has grown from just a handful of cases less than a year ago to more than 1,100 complaints, according to a joint report issued last month. The report also indicated that at least 3 defendants had been dismissed from liability in the lawsuits.
Taxotere Alopecia Lawsuit Filed in Louisiana
November 21, 2016 – A Louisiana woman who claims she lost hair that never came back after undergoing chemotherapy with Taxotere has filed a lawsuit against Sanofi-Aventis. Plaintiff Irene Guidry alleges that she lost hair after chemo for breast cancer with Taxotere in 2011, and it never grew back. She claims that Sanofi marketed the drug as superior to other chemotherapy treatments, without warning that the risk of hair loss may be permanent, while this is only a temporary side effects in similar products.
Taxotere Alopecia Lawsuit Filed in Minnesota
August 19, 2016 – A Minnesota woman who allegedly experienced permanent hair loss after chemotherapy with Taxotere has filed a lawsuit against Sanofi-Aventis. Plaintiff Kristin Anderson alleges the company failed to warn of the risk of permanent alopecia with Taxotere, and falsely marketed the drug as superior to other chemo treatments with no scientific evidence to back this claim.
Do I Have a Taxotere Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Taxotere lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Evaluation: Again, if you had permanent hair loss (alopecia) or baldness after chemotherapy treatment with Taxotere, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and we can help.